Hypertriglyceridemia Associated with Use of Sunitinib to Treat a Metastatic Pancreatic Neuroendocrine Tumor
| Autor: | Chi Wha Han, Sanghoon Yoo, Gyo-Hui Kim, Yun Hwa Jung, In-Sook Woo, Youngyun Cho |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry Sunitinib Hypertriglyceridemia Neuroendocrine tumors medicine.disease Gastroenterology Tyrosine-kinase inhibitor Endocrinology medicine.anatomical_structure Renal cell carcinoma Internal medicine medicine Pancreas business Esophagitis Tyrosine kinase medicine.drug |
| Zdroj: | Korean Journal of Medicine. 88:101 |
| ISSN: | 2289-0769 1738-9364 |
| DOI: | 10.3904/kjm.2015.88.1.101 |
| Popis: | Sunitinib is a multi-target tyrosine kinase inhibitor used to treat gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. The most common adverse reactions are known to be nausea, fatigue, diarrhea, stomatitis, esophagitis, hypertension, skin toxicity (hand-foot syndrome), hypothyroidism, and reduction in the cardiac output of the left ventricle. Herein, we report the case of a 57 year-old female who visited our hospital complaining of epigastric pain. She had been taking sunitinib at 25 mg/day to treat a metastatic pancreatic neuroendocrine tumor. Upon computed tomography performed on admission, we observed that fluid had collected around the pancreas. Laboratory analysis revealed hypertriglyceridemia (triglycerides 993 mg/dL). Tyrosine kinase inhibitors are known to have limited effects on lipid metabolism. In this case, we suggest that hyperglycemia seems to have had a limited effect on lipid levels. We are rather of the view that hyperglycemia, a history of distal pancreatectomy, and hypothyrodisim, indirectly caused the observed hypertriglyceridemia. (Korean J Med 2015;88:101-105) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|